University Hospitals Case Medical Center

Monthly News – December 2012

Department of Psychiatry

December 17, 2012 Volume 6, Number 12

General News

Dr. Molly McVoy was quoted in a Plain Dealer article on December 3rd regarding the DSM V. Dr. McVoy is a member of the APA committee that approved the latest edition of the Diagnostic and Statistical Manual of Mental Diseases, or DSM-5 on December 1, 2012. Dr. McVoy explained the significance of the changes in diagnoses for providers and patients.

Awards and Recognition:

PGY-4 Child and Adolescent Psychiatry fellow, **Dr. Sarah Lytle,** has been selected as a GAP Fellow for 2013-2014. The Group for Advancement of Psychiatry (GAP) Fellowship is a program for outstanding residents and fellows given the opportunity to work in an informal setting with leaders in psychiatry. The GAP meets semiannually in a think-tank format where leaders in psychiatry discuss contemporary issues confronting the profession. Members work in small committees to explore the interface between science, social issues, and psychiatry. Important ideas are communicated to the mental health field and to the public through written and electronic media.

Congratulations:

Dr. Ashleigh Anderson, PGY-4 Child and Adolescent psychiatry fellow, and her husband Colin welcomed their first born, Graham Thomas Anderson on November 20, 1012.

Dr. John Herzter was appointed as Interim Chairman of the Division of Child and Adolescent Psychiatry on December 1, 2012, following the departure of Dr. Robert L. Findling.

Dr. Molly McVoy passed her Child and Adolescent Psychiatry board exams.

Grand Rounds:

December 21st:
Speaker: Binit Shah, M.D.
Topic: Interface between Psychiatry & Pain

December 28th:
NO GRAND ROUNDS

January 4th:
Speaker: Tanvir Syed, M.D., M.P.H.
Topic: Psychogenic Nonepileptic Seizures: Diagnosis, Etiology, and Treatment

January 11th:
James Horner lecture
Speaker: Stacy S Drury, MD, PhD
Topic: Rethinking Risk and Resiliency

January 18th
Speaker: Phillip J. Resnick, M.D.
Topic: Neonaticide: Murder of the Newborn

January 25th:
Morley/Mather Lecture in Neuropsychiatry – Please note, this lecture will be held in Kulas Auditorium in Lakeside.
Speaker: David M. Fresco, Ph.D.
Topic: TBA

**** Reception immediately following the lecture in the Mayer-Haber Conference Room 13-113***

Presentations and Publications:

Lori Locke, RN, MSN, and **Karen Federspiel, RN-BC, CNS** presented posters at the American Psychiatric Nurses Association meeting in Pittsburgh Nov 7th – 10th.

Lori Locke presented *"UH System Psychoses Readmissions Reduction Strategy,"* and **Karen Federspiel**, presented "*University Hospitals Department of Psychiatry: Design of New Rainbow and Richmond Inpatient Facilities."*

Pagano, M. E., Kelly, J. F., **Scur, M. D., Ionescu, R. A.**, Stout, R. L., Post, S. G. (2013). Assessing Youth Participation in AA-Related Helping: Validity of the Service to Others in Sobriety (SOS) Questionnaire in an Adolescent Sample. *American Journal on Addictions, 22*(1). 1-7, (In Press).

Pagano, M.E., White, W.L., Kelly, J.F., Stout, R.L., & Tonigan, J.S. (2012). The 10-Year course of AA participation and long-term outcomes: A follow-up study of outpatient subjects in Project MATCH. *Substance Abuse 34*(1), 1-9. (In Press).

Research:

University Hospitals is now conducting a research study of an investigational medication for Generalized Anxiety, Separation Anxiety and Social Phobia. Participants must be between the ages of 6 and 17 years. Children with these disorders may have an excessive fear of being alone, refuse to go to school, avoid social situations, or have difficulty sleeping. If eligible for this study, participants may receive mental health assessments, investigational medication and close follow up with a doctor who specializes in pediatric mental health at no cost. For more information, please call 216-844-3922.

The Discovery and Wellness Center for Children at University Hospitals Case Medical Center is currently enrolling children ages 7-17 with Tourette's Disorder for a research study. Participants must be experiencing frequent motor and/or vocal tics that cause impairment in the child's normal routines. This study can be up to an 18 week period of involvement with only 8 weeks receiving investigational medication. This clinical study includes study-related physical exams and study medication or placebo at no charge. To learn more about this clinical trial, please call Becky Weintraub at 216-844-3922.

SMI and Diabetes study

Do you have any patients with **Serious Mental Illness** (i.e., Current MDE, Bipolar Disorder, or Schizophrenia/Schizoaffective Disorder) and **Type 2 Diabetes** (DM)? Could they benefit from learning more about how to manage their SMI and Diabetes?

Dr. Sajatovic's Research Team in collaboration with CWRU's Center for Healthcare Research and Policy (CHRP) at MetroHealth Medical Center is conducting a Randomized Controlled Trial comparing a novel intervention (TTIM) intended to improve both SMI and DM self-management in 100 individuals with SMI-DM vs. 100 individuals with SMI-DM receiving treatment as usual (TAU).

Basic Inclusion/Exclusion Criteria includes:

Participants MUST:

- Have a diagnosis of schizophrenia, schizoaffective disorder, bipolar disorder or depression;
- Have DM based upon either previous diagnosis or laboratory values; and
- Be ≥ 18 years of age;

Participants CANNOT:

- Have dementia; or
- Be pregnant.

Individuals will be randomized on a 1:1 basis to participate in either TTIM or TAU. Those randomized to TTIM will receive twelve weekly, group-format, in-person sessions (6-10 participants per group) delivered by a primary care Nurse Educator with experience and training in both DM and SMI treatment, and by a Peer Educator with SMI-DM. Over the 48 weeks following the TTIM sessions, the TTIM participants will receive periodic follow-up phone calls from the Peer Educator and in-person visits with the Nurse Educator to provide support by way of encouraging care engagement and healthy behaviors as well as addressing questions that may arise from a "consumer" perspective.

Primary and secondary outcome assessments will be repeated for both the TTIM and TAU participants at weeks 13, 30, and 60. Qualitative assessment for a subset of participants will be conducted at 13 weeks. **Regardless of which group they are randomized to, all participants will *continue to receive their psychiatric and medical care from their usual providers* throughout the study.**

If you have any questions or would like to refer a possible participant, please contact Edna Fuentes-Casiano at 216-844-2104 or edna.fuentes-casiano@uhhospitals.org.

Contact:

Published by University Hospitals Dept. of Psychiatry
DEADLINE FOR NEXT ISSUE: Friday, 01/18/2013

CONTACT: Kate Kilbane
Phone: 216-844-3658
kate.kilbane@uhhospitals.org